Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
1.
Transl Psychiatry ; 7(1): e1014, 2017 01 31.
Article in English | MEDLINE | ID: mdl-28140403

ABSTRACT

The environmental contributions to autism spectrum disorder (ASD) and their informative content for diagnosing the condition are still largely unknown. The objective of this study was to investigate associations between early medical events and ASD, as well as autistic traits, in twins, to test the hypothesis of a cumulative environmental effect on ASD risk. A total of 80 monozygotic (MZ) twin pairs (including a rare sample of 13 twin pairs discordant for clinical ASD) and 46 dizygotic (DZ) twin pairs with varying autistic traits, were examined for intra-pair differences in early medical events (for example, obstetric and neonatal factors, first year infections). First, differences in early medical events were investigated using multisource medical records in pairs qualitatively discordant for ASD. The significant intra-pair differences identified were then tested in relation to autistic traits in the remaining sample of 100 pairs, applying generalized estimating equations analyses. Significant association of the intra-pair differences in the MZ pairs were found for the cumulative load of early medical events and clinical ASD (Z=-2.85, P=0.004) and autistic traits (ß=78.18, P=0.002), as well as infant dysregulation (feeding, sleeping abnormalities, excessive crying and worriedness), when controlling for intelligence quotient and attention deficit hyperactivity disorder comorbidity. The cumulative load of early medical events in general, and infant dysregulation in particular, may index children at risk of ASD owing to non-shared environmental contributions. In clinical practice, these findings may facilitate screening and early detection of ASD.


Subject(s)
Autistic Disorder/psychology , Environment , Twins, Dizygotic , Twins, Monozygotic , Adolescent , Adult , Apgar Score , Asthma/epidemiology , Attention Deficit Disorder with Hyperactivity/epidemiology , Attention Deficit Disorder with Hyperactivity/psychology , Autism Spectrum Disorder/epidemiology , Autism Spectrum Disorder/psychology , Autistic Disorder/epidemiology , Birth Weight , Breech Presentation/epidemiology , Cerebral Hemorrhage/epidemiology , Child , Eczema/epidemiology , Epilepsy/epidemiology , Feeding and Eating Disorders of Childhood/epidemiology , Female , Fetal Distress/epidemiology , Gastroenteritis/epidemiology , Heart Defects, Congenital/epidemiology , Humans , Hydrocephalus/epidemiology , Hyperbilirubinemia, Neonatal/epidemiology , Hypersensitivity/epidemiology , Hypoglycemia/epidemiology , Male , Microcephaly/epidemiology , Otitis Media/epidemiology , Oxygen Inhalation Therapy , Pregnancy , Pyelonephritis/epidemiology , Sepsis/epidemiology , Sleep Wake Disorders/epidemiology , Sweden/epidemiology , Thrombocytopenia/epidemiology , Vision Disorders/epidemiology , Young Adult
2.
Neuroscience ; 298: 302-17, 2015 Jul 09.
Article in English | MEDLINE | ID: mdl-25892702

ABSTRACT

L-3,4-Dihydroxyphenylalanine (L-DOPA) is the therapeutic gold standard in Parkinson's disease. However, long-term treatment is complicated by the induction of debilitating abnormal involuntary movements termed L-DOPA-induced dyskinesias (LIDs). Until today the underlying mechanisms of LID pathogenesis are not fully understood. The aim of this study was to reveal new factors, which may be involved in the induction of LID. We have focused on the expression of striatal tyrosine hydroxylase-positive (TH+) neurons, which are capable of producing either L-DOPA or dopamine (DA) in target areas of ventral midbrain DAergic neurons. To address this issue, a daily L-DOPA dose was administered over the course of 15 days to mice with unilateral 6-hydroxydopamine-induced lesions of the medial forebrain bundle and LIDs were evaluated. Remarkably, the number of striatal TH+ neurons strongly correlated with both induction and severity of LID as well as ΔFosB expression as an established molecular marker for LID. Furthermore, dyskinetic mice showed a marked augmentation of serotonergic fiber innervation in the striatum, enabling the decarboxylation of L-DOPA to DA. Axial, limb and orolingual dyskinesias were predominantly associated with TH+ neurons in the lateral striatum, whereas medially located TH+ neurons triggered locomotive rotations. In contrast, identified accumbal and cortical TH+ cells did not contribute to the generation of LID. Thus, striatal TH+ cells and serotonergic terminals may cooperatively synthesize DA and subsequently contribute to supraphysiological synaptic DA concentrations, an accepted cause in LID pathogenesis.


Subject(s)
Corpus Striatum/pathology , Dyskinesia, Drug-Induced/pathology , Functional Laterality/physiology , Neurons/metabolism , Tyrosine 3-Monooxygenase/metabolism , Amphetamine/pharmacology , Animals , Antiparkinson Agents/adverse effects , Disease Models, Animal , Dyskinesia, Drug-Induced/etiology , Levodopa/adverse effects , Male , Medial Forebrain Bundle/drug effects , Medial Forebrain Bundle/injuries , Mice , Mice, Inbred C57BL , Oxidopamine/toxicity , Parkinson Disease/drug therapy , Parkinson Disease/etiology , Phosphopyruvate Hydratase/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism , Statistics, Nonparametric
3.
Mol Neurobiol ; 52(3): 1152-1164, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25307288

ABSTRACT

Alpha-synuclein (SNCA) protein aggregation plays a causal role in Parkinson's disease (PD). The SNCA protein modulates neurotransmission via the SNAP receptor (SNARE) complex assembly and presynaptic vesicle trafficking. The striatal presynaptic dopamine deficit is alleviated by treatment with levodopa (L-DOPA), but postsynaptic plastic changes induced by this treatment lead to a development of involuntary movements (dyskinesia). While this process is currently modeled in rodents harboring neurotoxin-induced lesions of the nigrostriatal pathway, we have here explored the postsynaptic supersensitivity of dopamine receptor-mediated signaling in a genetic mouse model of early PD. To this end, we used mice with prion promoter-driven overexpression of A53T-SNCA in the nigrostriatal and corticostriatal projections. At a symptomatic age (18 months), mice were challenged with apomorphine (5 mg/kg s.c.) and examined using both behavioral and molecular assays. After the administration of apomorphine, A53T-transgenic mice showed more severe stereotypic and dystonic movements in comparison with wild-type controls. Molecular markers of extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation and dephosphorylation, and Fos messenger RNA (mRNA), were examined in striatal tissue at 30 and 100 min after apomorphine injection. At 30 min, wild-type and transgenic mice showed a similar induction of phosphorylated ERK1/2, Dusp1, and Dusp6 mRNA (two MAPK phosphatases). At the same time point, Fos mRNA was induced more strongly in mutant mice than in wild-type controls. At 100 min after apomorphine treatment, the induction of both Fos, Dusp1, and Dusp6 mRNA was significantly larger in mutant mice than wild-type controls. At this time point, apomorphine caused a reduction in phospho-ERK1/2 levels specifically in the transgenic mice. Our results document for the first time a disturbance of ERK1/2 signaling regulation associated with apomorphine-induced involuntary movements in a genetic mouse model of synucleinopathy. This mouse model will be useful to identify novel therapeutic targets that can counteract abnormal dopamine-dependent striatal plasticity during both prodromal and manifest stages of PD.


Subject(s)
Apomorphine/toxicity , Dyskinesias/etiology , Locomotion/drug effects , MAP Kinase Signaling System/physiology , Parkinsonian Disorders/physiopathology , Stereotyped Behavior/drug effects , alpha-Synuclein/genetics , Animals , Corpus Striatum/metabolism , Corpus Striatum/pathology , Corpus Striatum/physiopathology , Disease Models, Animal , Dopaminergic Neurons/pathology , Dopaminergic Neurons/physiology , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/genetics , Mice , Mice, Transgenic , Mutation, Missense , Nerve Tissue Proteins/metabolism , Parkinsonian Disorders/genetics , Phosphorylation/drug effects , Point Mutation , Post-Synaptic Density/drug effects , Prions/genetics , Promoter Regions, Genetic , Protein Processing, Post-Translational/drug effects , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Transgenes
4.
Open Ophthalmol J ; 6: 42-8, 2012.
Article in English | MEDLINE | ID: mdl-22754600

ABSTRACT

AIM: The aim of the study was to investigate changes in cell adhesion molecule expression in human lens epithelial cells (HLEC) subjected to glucocorticoids. METHODS: Human lens epithelial cells were exposed to different concentrations of dexamethasone for 24 hours. Cell adhesion molecule expression was studied by western blot and immunohistochemistry of vimentin, N-cadherin, E-cadherin, α-catenin, ß-catenin and γ-catenin. Expression of the glucocorticoid receptor (GR) was also studied. Cell morphology was examined by transmission electron microscopy (TEM). RESULT: Expression of N-cadherin, α-catenin, ß-catenin and GR was significantly decreased in dexamethasone exposed cells as compared to unexposed cells. No significant change in γ-catenin was present. Visualization of adhesion molecules, N-cadherin and α-catenin, by immunohistochemistry showed decreased antigen reactivity in dexamethasone exposed as compared to the unexposed cells. However, no change was seen for ß-catenin and γ-catenin. E-cadherin was not detectable using western blot or immunohistochemistry. TEM showed multilayering of cells, vacuole formation and appearance of electron-dense multivesicular bodies in HLEC exposed to 0, 0.1, 1, 10 and 100 αM dexamethasone. CONCLUSION: Glucocorticoids affect several adhesion molecules in lens epithelial cells, something that may contribute to the pathogenesis of posterior subcapsular opacification.

5.
Phys Chem Chem Phys ; 13(35): 16084-94, 2011 Sep 21.
Article in English | MEDLINE | ID: mdl-21814675

ABSTRACT

We study the compressive behaviour of a polymer-covered surface (i.e., a "polymer brush") using Brownian dynamics simulations. The model consists of grafted chains with variable flexibility, variable intra- and inter-chain interactions, as well as different surface coverage. We discuss the polymer brush response to confinement by considering variable rates of compression under a hard plane. Our results show a small degree of inter-chain entanglement, regardless of whether the interaction is attractive or merely excluded volume. We observe that the molecular shape depends strongly on the surface coverage. Dense brushes exhibit a limited degree of lateral deformation under compression; instead, chains undergo a transition that produces a local patch with near-solid packing. This effect due to surface density can be undone partially by increasing the attractive nature of the chain interaction, by modulating the rate of compression, or by allowing "soft anchoring", i.e., the possible Brownian drift of the grafting bead on the surface. We have also studied the polymer brush relaxation while maintaining the compressing plane, as well as after its sudden removal. We find evidence that also the relaxation depends on surface density; dense brushes appear to be configurationally frustrated at high compression and are unable to undergo swelling, regardless of the pressure applied.


Subject(s)
Polymers/chemistry , Adsorption , Molecular Dynamics Simulation , Static Electricity , Surface Properties
6.
Phys Chem Chem Phys ; 13(24): 11757-65, 2011 Jun 28.
Article in English | MEDLINE | ID: mdl-21603703

ABSTRACT

We present Brownian dynamics simulations of single grafted semiflexible chains (i.e., "polymer mushrooms") with varying persistence lengths, intra-chain interactions, and subject to confinement. The results from different rates of compression are presented in the cases of an approaching infinite plane and a paraboloid tip. We discuss the different behaviour observed for grafted chains with strong and weak self-attraction (i.e., "hard" and "soft" polymer mushrooms). In both cases the effect on the size and shape is more pronounced for a slow compression rate, especially for "hard mushrooms". We have also studied the relaxation of the chain while the compressing plane is maintained, and when it is removed suddenly. We find that the response depends strongly on the time allowed for relaxation in the compressed state. When using instead a paraboloid tip, the overall effects are similar yet less pronounced because the chain can dodge the confining object via an "escape transition."


Subject(s)
Polymers/chemistry , Models, Chemical , Molecular Dynamics Simulation
7.
Mol Vis ; 14: 1344-52, 2008 Jul 21.
Article in English | MEDLINE | ID: mdl-18648526

ABSTRACT

PURPOSE: Treatment with glucocorticoids is a well known risk factor for cataract development, although the pathogenic mechanism has not been elucidated. The aim of the study was to investigate the effects of glucocorticoids in cultured human lens epithelial cells. METHODS: Human lens epithelial cells (HLECs) were exposed to dexamethasone for 24 h. The number of viable cells was determined using the 3-[4, 5-dimethylthiazolyl-2]-2, 5-diphenyltetrazolium bromide (MTT) assay, and proliferation was quantified using Ki-67. Apoptosis was investigated by measuring caspase-3 activity and by evaluating nuclear morphology of cells stained with Hoechst 33342. Mitochondria depolarization was measured using the potential-sensitive color, JC-1. Cells were assayed for changes in superoxide production using dihydroethidium (HET), for alterations in peroxide production using dichlorofluorescein diacetate (DCFH-DA), and for glutathione (GSH) variations using monochlorobimane (MCB). Caspase-3 activity was also measured in HLECs simultaneously exposed to dexamethasone and the glucocorticoid antagonist, RU486. RESULTS: Low doses of dexamethasone (0.1 microM) resulted in increased proliferation of HLECs. Apoptosis was increased in HLECs exposed to 1 microM, 10 microM, and 100 microM of dexamethasone as revealed by nuclear morphology studies. Apoptosis was also confirmed by measuring caspase-3 activation. No effect on superoxide production by dexamethasone was seen. There were no effects on GSH levels or mitochondrial depolarization either. Only the highest concentration of dexamethasone (100 microM) caused an increase in peroxide production. In HLECs incubated with the glucocorticoid antagonist, RU486, apoptosis was induced at a lower concentration of dexamethasone (0.1 microM) than with dexamethasone alone. CONCLUSIONS: Low doses of dexamethasone cause a moderate increase in proliferation of cultured HLECs. Slightly higher but still physiologically relevant concentrations of dexamethasone result in a dose-dependent increase in apoptosis. Dexamethasone-induced apoptosis in HLECs does not seem to involve oxidative mechanisms. The proapoptotic effect of dexamethasone does not appear to act through the glucocorticoid receptor. Effects on proliferation and/or dysregulation of apoptosis in lens epithelial cells may be an important factor in human steroid-induced posterior subcapsular cataract.


Subject(s)
Dexamethasone/pharmacology , Epithelial Cells/drug effects , Lens, Crystalline/cytology , Apoptosis/drug effects , Caspase 3/metabolism , Cell Count , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Epithelial Cells/enzymology , Glutathione/metabolism , Humans , Immunohistochemistry , Lens, Crystalline/enzymology , Membrane Potential, Mitochondrial/drug effects , Mifepristone/pharmacology , Peroxides/metabolism , Receptors, Glucocorticoid/antagonists & inhibitors , Superoxides/metabolism
8.
Med Chem ; 4(1): 1-10, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18220966

ABSTRACT

The novel 4-phenoxy-1,2,3,4-tetrahydroisoquinolines 6a-c and their rigid congeners 4,5,6,6a-tetrahydro-chromeno[2,3,4-de]isoquinolines 7a,b were synthesized in order to obtain dopamine D2-like receptor ligands. The new compounds were evaluated for their in vitro binding affinities, in vivo behavioral activities on rats, and for their effects on rat brain neurochemistry. Compounds 6b (toward both D2 and D3 dopamine receptors) and 7a,b (toward D3 only dopamine receptors) showed the most significant affinities. However none of the new compounds was able to stimulate behavioral activity in non pre-treated rats, nor to influence brain neurochemistry.


Subject(s)
Dopamine Agonists/chemical synthesis , Dopamine Agonists/pharmacology , Isoquinolines/chemical synthesis , Isoquinolines/pharmacology , 3,4-Dihydroxyphenylacetic Acid/chemistry , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Brain/drug effects , Brain/metabolism , Dopamine Agonists/chemistry , Dopamine Agonists/metabolism , Dose-Response Relationship, Drug , Humans , Isoquinolines/chemistry , Isoquinolines/metabolism , Motor Activity/drug effects , Neurochemistry , Rats , Receptors, Dopamine/metabolism
9.
Ophthalmic Res ; 40(2): 77-85, 2008.
Article in English | MEDLINE | ID: mdl-18223300

ABSTRACT

The aim of the study was to examine the effects of nonsteroidal anti-inflammatory drugs (NSAIDs)/acetylsalicylic acid (ASA) on human lens epithelial cells (HLECs) during oxidative stress. HLECs were exposed to H2O2 in the absence or presence of indomethacin, diclofenac, celecoxib (NSAIDs) or ASA for 24 h. HLECs were assayed for changes in superoxide and peroxide production and for variations in glutathione. Mitochondrial depolarization was measured using the membrane potential-sensitive dye JC-1. The results of the study include reduction in superoxide and peroxide production as well as reduction in glutathione depletion in oxidatively stressed HLECs incubated with low concentrations of NSAIDs/ASA. However, no protection against H2O2-induced mitochondrial depolarization by NSAIDs/ASA could be seen. In conclusion, NSAIDs/ASA display reactive oxygen species-scavenging properties in H2O2-exposed HLECs in culture.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Aspirin/pharmacology , Intracellular Membranes/drug effects , Lens, Crystalline/drug effects , Lens, Crystalline/metabolism , Oxidative Stress , Celecoxib , Cell Size , Cells, Cultured , Diclofenac/pharmacology , Epithelial Cells/cytology , Epithelial Cells/drug effects , Free Radical Scavengers/pharmacology , Glutathione/antagonists & inhibitors , Glutathione/metabolism , Humans , Hydrogen Peroxide/pharmacology , Indomethacin/pharmacology , Lens, Crystalline/cytology , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Oxidants/pharmacology , Peroxides/antagonists & inhibitors , Pyrazoles/pharmacology , Reactive Oxygen Species/metabolism , Sulfonamides/pharmacology , Superoxides/antagonists & inhibitors
10.
Curr Eye Res ; 32(10): 871-82, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17963107

ABSTRACT

PURPOSE: This study aimed to investigate redox regulation of the proteasome as well as the effect of proteasome inhibition on intracellular oxidative status and apoptosis. METHODS: Oxidative stress was induced in cultured human lens epithelial cells (HLECs) and intact mouse lenses by 100 microM H2O2. HLECs were also exposed to the reduced and the oxidized forms of glutathione (GSH/GSSG) and the reducing agent dithiotreitol (DTT). The chymotrypsin-like, the trypsin-like, and the peptidylglutamyl peptidase activities of the proteasome were measured using synthetic fluorogenic substrates. Superoxide as well as peroxide production, mitochondrial membrane potential, and the level of GSH was measured in HLECs after proteasome inhibition by MG-132 or lactacystin. Apoptosis was determined by measuring caspase-3 activation and by studying apoptotic nuclei after staining with Hoechst 33342. RESULTS: All three peptidase activities of the proteasome were inhibited by 100 microM H2O2 and by the oxidized form of glutathione (GSSG), whereas the reduced form (GSH) stimulated chymotrypsin-like and peptidylglutamyl peptidase activities in HLECs lysates. Intact mouse lenses exposed to 100 microM H2O2 exhibited loss of transparency and trends of decreased chymotrypsin-like proteasome activity as well as decreased GSH levels. Inhibition of the proteasome in cultured HLECs caused significant increase in apoptosis and disturbed intracellular redox balance. Simultaneous addition of exogenous GSH completely abolished the increased apoptosis seen after MG-132 treatment. CONCLUSIONS: This study supports the hypothesis that intracellular proteolytic and oxidative regulatory systems are tightly coupled. The current data also indicate that apoptosis by proteasome inhibition is mediated through oxidative mechanisms.


Subject(s)
Apoptosis/physiology , Intracellular Membranes/metabolism , Lens, Crystalline/physiology , Proteasome Endopeptidase Complex/metabolism , Acetylcysteine/analogs & derivatives , Acetylcysteine/pharmacology , Animals , Apoptosis/drug effects , Cells, Cultured , Cysteine Proteinase Inhibitors/pharmacology , Epithelial Cells/physiology , Glutathione/pharmacology , Glutathione Disulfide/pharmacology , Humans , Hydrogen Peroxide/pharmacology , In Vitro Techniques , Lens, Crystalline/cytology , Leupeptins/pharmacology , Mice , Oxidants/pharmacology , Oxidation-Reduction , Oxidative Stress , Peptide Hydrolases/metabolism
11.
Phys Rev E Stat Nonlin Soft Matter Phys ; 76(1 Pt 1): 011704, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17677468

ABSTRACT

Using x-ray and optical methods we have probed the structural organization of an antiferroelectric twist grain boundary phase (TGBC(a)) lying between the regular antiferroelectric smectic-C (SmC(a)* and the smectic-Q (SmQ) or isotropic phase. We find that the twist axis is everywhere perpendicular to the local smectic layer normal and that the helical superstructure is incommensurate with the smectic layer structure. The twist grain boundaries consist of a periodic lattice of alternating +1/2 and -1/2 dispirations, i.e., unit screw dislocations in combination with half unit disclinations. The molecular tilt plane is alternatingly parallel and perpendicular to the twist axis. We find that the optically measured tilt angle in the SmC(a)* phase is smaller than that measured by x rays, which is the opposite to what is found in the SmC* phase. This means that the core part tilts less than the end chains in the SmC(a)* phase, while it tilts more in the SmC* phase. On entering the TGB phase a clear decrease is measured in the tilt angle. This is explained by the elastic influence from the disclinations, which appear in this phase.

12.
J Hosp Infect ; 66(4): 378-84, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17573155

ABSTRACT

We carried out a one-day prevalence survey of hospital-acquired infections (HAIs) and antimicrobial use in February 2006 in a paediatric hospital in Arkhangelsk, north-western Russia. A total 472 patients aged less than 18 years old were included in the study, of which 395 (84%) had been inpatients in the hospital for at least 48 h on the study day. The overall prevalence of HAI amongst the latter group of patients was 17% [67/395; 95% confidence interval (CI): 13.8-21.2] with upper respiratory tract infections being most frequently diagnosed (45%), followed by lower respiratory tract infections (19%) and urinary tract infections (12%). The highest proportion of HAI was found in patients less than one year old and in those with hospital stays of longer than 10 days. Antimicrobial agents were given to 39% of all hospitalized patients (183/472; 95% CI: 34.5-43.2). Cephalosporins accounted for 39% (82/211) of all antimicrobial prescriptions, followed by the penicillins (22%; 46/211). This study established a baseline for surveillance of HAI and antimicrobial use within the hospital, and facilitated the adoption of targeted infection control measures.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/epidemiology , Cross Infection/epidemiology , Adolescent , Age Factors , Anti-Bacterial Agents/classification , Bacterial Infections/drug therapy , Child , Child, Preschool , Cross Infection/drug therapy , Cross-Sectional Studies , Female , Hospitals, Pediatric/statistics & numerical data , Humans , Infant , Infant, Newborn , Length of Stay , Male , Prevalence , Russia/epidemiology , Sentinel Surveillance
13.
Phys Rev E Stat Nonlin Soft Matter Phys ; 75(3 Pt 1): 031109, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17500670

ABSTRACT

We show how the irreducible memory function can be obtained in a rather straightforward way, and that it can be expressed in terms of two contributions representing two parallel decay channels. This representation should be useful for treating systems with a slow time dependence and where eventually some internal degrees of freedom enters in the relaxation process, and cuts off an underlying ideal ergodic to nonergodic transition. We also show how the irreducible memory function under certain mild conditions defines a regenerative stochastic process, or a two level stochastic system. This leads to a picture with dynamical heterogeneities, where the statistical properties asymptotically are ruled by limit processes. This can explain the universal behavior observed in many glass-forming systems.

14.
Neuroscience ; 141(1): 521-31, 2006 Aug 11.
Article in English | MEDLINE | ID: mdl-16697115

ABSTRACT

Functional recovery following intrastriatal transplantation of fetal dopaminergic neurons in animal models of Parkinson's disease is, at least in part, dependent on the number of surviving dopaminergic neurons and the degree of graft-derived dopaminergic reinnervation of the host striatum. In the present study, we analyzed whether continuous exposure of glial cell line-derived neurotrophic factor (GDNF) to mature dopaminergic grafts could further boost the functional outcome of widespread intrastriatal dopaminergic grafts. Rats with dopamine-denervating lesions received multiple intrastriatal transplants of fetal dopaminergic cells and graft-induced behavioral effects were analyzed in drug-induced and spontaneous motor behaviors. At three months after grafting, animals received intrastriatal injections of recombinant lentiviral vectors encoding for either human GDNF or the green fluorescent protein. Continuous exposure of GDNF to the grafts did not boost the functional recovery beyond what was observed in the control animals. Rather, in some of the spontaneous motor behaviors, animals in the GDNF-group showed deterioration as compared with control animals, and this negative effect of GDNF was associated with a down-regulation of the tyrosine hydroxylase enzyme. Based on these and our earlier results, we propose that intrastriatal administration of GDNF at the time of or shortly after grafting is highly effective in initially promoting the cell survival and fiber outgrowth from the grafts. However, once the grafts are mature, GDNF's ability to boost dopaminergic neurotransmission follows the same dynamics as for the native nigral dopaminergic neurons, which appears to be dependent on the concentration of GDNF. Since rather low doses of glial cell line-derived neurotrophic factor at nanogram levels appear to saturate these effects, it may be critical to adjust GDNF levels using tightly regulated gene expression systems.


Subject(s)
Cell Transplantation/methods , Dopamine/metabolism , Glial Cell Line-Derived Neurotrophic Factor/administration & dosage , Motor Activity/drug effects , Parkinson Disease/drug therapy , Parkinson Disease/surgery , Analysis of Variance , Animals , Apomorphine/pharmacology , Behavior, Animal , Cell Count/methods , Corpus Striatum/cytology , Corpus Striatum/metabolism , Corpus Striatum/transplantation , Disease Models, Animal , Drug Interactions , Female , Green Fluorescent Proteins/metabolism , Motor Activity/physiology , Neurons/drug effects , Neurons/metabolism , Psychomotor Performance/drug effects , Psychomotor Performance/physiology , Rats , Rats, Sprague-Dawley , Recovery of Function/drug effects , Recovery of Function/physiology , Rotarod Performance Test/methods , Transplants , Tyrosine 3-Monooxygenase/metabolism , Vesicular Monoamine Transport Proteins/metabolism
15.
J Viral Hepat ; 13(5): 316-21, 2006 May.
Article in English | MEDLINE | ID: mdl-16637862

ABSTRACT

Standard therapy for chronic hepatitis C (HCV) is pegylated interferon in combination with ribavirin. There is limited experience with either drug in dialysis [end stage renal disease (ESRD)]. Six haemodialysis patients, four with HCV genotype 1, one with genotype 4 and one genotype 2 were treated with pegylated interferon-alfa-2b (n = 4) and pegylated interferon-alfa-2a (n = 2) for 24-48 weeks according to genotype with a dose of 50 or 135 mug/week respectively. All patients were given reduced ribavirin doses, initially 200-400 mg/day. Ribavirin trough plasma concentrations were measured with a HPLC method previously developed for earlier treatment studies, aiming at a target concentration of 10-15 micromol/L. Interferon related side-effects were common, in one patient peg-alfa-2b was permanently reduced to 50 mug every 9-10 days with improvement in tolerance. Average ribavirin dose was 170-300 mg/day. Ribavirin-induced anaemia was treated with high doses of erythropoietin and low doses of iron. Blood-transfusions were not needed. All patients became HCV-RNA-PCR negative during treatment which was completed or nearly completed in four patients. One patient terminated therapy prematurely due to pronounced interferon related side-effects and another died of myocardial infarction probably not related to therapy. Three patients have remained HCV-RNA negative with extended follow-up, two of whom have had a successful kidney transplant. Pegylated interferons are likely to become a valuable addition for HCV therapy in ESRD and are possible to combine with ribavirin. However the pharmacokinetics and tolerability of both peg-alfa-2a and 2b need to be studied more closely in prospective studies before definite dosing recommendations can be made.


Subject(s)
Hepacivirus/growth & development , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Kidney Failure, Chronic/virology , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Adult , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Drug Therapy, Combination , Female , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Kidney Failure, Chronic/therapy , Male , Middle Aged , Polyethylene Glycols/adverse effects , RNA, Viral/blood , Recombinant Proteins , Renal Dialysis , Retrospective Studies , Ribavirin/adverse effects
17.
J Viral Hepat ; 12(5): 473-80, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16108761

ABSTRACT

SUMMARY: To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log10 decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a 2-log10 decrease in HCV RNA levels at day 7, the positive predictive value (PPV) for a SVR was 92%, whereas week 12 was the best time point for predicting a later nonresponse [negative predictive value (NPV) 92%] in patients failing to achieve a 2-log10 drop. For patients with genotype non-1 and a 2-log10 decrease in HCV RNA levels the PPV for a SVR was 89% week 1, and 79% weeks 4 and 12. The corresponding NPV for patients with genotype non-1 were 43, 40 and 100% respectively. During treatment with pegylated interferon alpha-2a plus ribavirin the HCV RNA decline at week 1 was an accurate predictor of SVR in patients who had achieved a 2-log10 drop in HCV RNA levels, whereas the lack of such decline week 12 was an accurate marker of a nonresponse.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Ribavirin/therapeutic use , Adult , Drug Therapy, Combination , Female , Hepacivirus/genetics , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/metabolism , Male , Middle Aged , Polyethylene Glycols/metabolism , RNA, Viral/blood , RNA, Viral/drug effects , Recombinant Proteins , Treatment Outcome , Viremia/drug therapy
18.
Scand J Gastroenterol ; 37(10): 1228-34, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12408530

ABSTRACT

BACKGROUND: The early decline of hepatitis C virus (HCV) RNA levels during therapy may predict the outcome and can be utilized to improve treatment regimens. We studied the HCV RNA levels during induction and standard interferon (IFN) and ribavirin treatment. METHODS: Patients received IFN 3 MU daily for 14 days followed by 3 MU three times a week (induction group; n = 10), or IFN 3 MU three times a week from start (standard group; n = 21), in combination with ribavirin 1000-1200 mg/day. HCV RNA was quantified day 0, 1, 2, 3, 7, 14, 28, 56 and 84 during treatment, and tested qualitatively at the end of treatment and at follow-up. RESULTS: The initial viral load decline was more pronounced in the induction group, and in patients infected with genotype non-1. The sustained response rate was not significantly different between the study groups. At day 1, the mean viral load decline from baseline was significantly greater in patients who became sustained responders than in those who became non-responders; 1.4 log (96%) versus 0.3 log (55%) (P < 0.05). All sustained responders had a viral load decline of at least 0.7 log (79%) after the first IFN dose. CONCLUSIONS: Our short-term induction treatment did not improve the long-term treatment outcome significantly, although a trend was seen. An absent or low initial viral load decline can be used to predict non-response in the individual patient.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepacivirus/isolation & purification , Hepatitis C/drug therapy , Hepatitis C/virology , Interferon-alpha/therapeutic use , Interferons/therapeutic use , Ribavirin/therapeutic use , Adult , Aged , Antiviral Agents/administration & dosage , Drug Therapy, Combination , Female , Follow-Up Studies , Hepacivirus/genetics , Hepatitis C/genetics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferons/administration & dosage , Male , Middle Aged , Recombinant Proteins , Remission Induction , Ribavirin/administration & dosage , Time Factors , Treatment Outcome
19.
Scand J Infect Dis ; 33(11): 838-42, 2001.
Article in English | MEDLINE | ID: mdl-11760165

ABSTRACT

We studied HCV kinetics during the first 84 d of interferon-alpha (IFN) treatment. IFN was administered either at a dose of 3 million units daily for the first 14 d and thereafter 3 times per week (t.i.w.) (induction treatment), or at a dose of 3 million units t.i.w. throughout (standard treatment). No patient had received HCV treatment previously, and all had a pretreatment viral load of < 1.2 x 10(6) IU/ml at screening. Ten patients were given induction treatment and 21 received the standard t.i.w. regimen. Twenty patients were infected with genotype 1. At Day 2, the median HCV RNA level in the induction group was significantly lower compared to that of the standard treatment group. This significant difference persisted during the study period for patients infected with genotype 1, but was not maintained from Day 14 onwards for patients with genotype non-1. At Day 84, 80% (8/10) of patients in the induction group, compared to 16% (3/19) in the standard treatment group, had undetectable (< 600 IU/ml) HCV RNA levels (p < 0.05). We conclude that induction treatment resulted in a significantly greater decline in HCV RNA levels than standard treatment.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepacivirus/genetics , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , RNA, Viral/drug effects , Adult , Antiviral Agents/administration & dosage , Female , Humans , Interferon-alpha/administration & dosage , Kinetics , Male , Middle Aged , RNA, Viral/metabolism , Treatment Outcome
20.
J Viral Hepat ; 7(6): 409-13, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11115051

ABSTRACT

Interferon (IFN) alpha in combination with ribavirin (RIB) is standard therapy for patients with chronic hepatitis C virus (HCV) infection. However, many patients do not respond with sustained HCV clearance to this therapy. At present, no accepted treatment strategy exists for these patients. Recent preliminary data have suggested that amantadine (AMA) is effective against HCV infection. In a pilot study, we treated 13 nonresponders and 10 response/ relapsers to previous IFN/RIB therapy with AMA 200 mg per day in combination with IFN 3 MU thrice weekly, and RIB 1000 mg per day for 24 weeks, with a 24-week follow-up period after end-of-treatment. At the end-of-treatment, 1 previous nonresponder and 5 previous response/relapsers were HCV RNA negative. At the end of follow-up, only 1 previous response/relapser remained HCV RNA negative and had a sustained response. During therapy, serum HCV RNA became undetectable in 4 previous nonresponders, of whom 3 had a breakthrough at week 24. Twenty-one patients continued therapy without dose reductions. One patient discontinued therapy prematurely due to sleeping disturbances, and another patient was withdrawn from therapy due to heavy alcohol intake. We conclude that the addition of AMA to IFN and RIB was well tolerated but had little, if any, impact on HCV RNA eradication in nonresponders or response/relapsers to previous IFN/RIB combination therapy.


Subject(s)
Amantadine/therapeutic use , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Ribavirin/therapeutic use , Adult , Drug Therapy, Combination , Female , Hepacivirus/isolation & purification , Hepacivirus/physiology , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Male , Middle Aged , Pilot Projects , RNA, Viral/blood , Recombinant Proteins , Recurrence , Treatment Failure , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...